Michael Woloschak

Learn More
OBJECTIVE This study assessed the efficacy and safety of once-weekly taspoglutide in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone compared with placebo. DESIGN In this randomized, double-blind, parallel-group, placebo-controlled trial (T-emerge 3), 326 patients were randomized to once-weekly sc injections(More)
INTRODUCTION The efficacy and safety of taspoglutide, a long-acting human glucagon-like peptide-1 analog, were compared with sitagliptin or placebo, as adjunct to metformin, in patients with inadequately controlled type 2 diabetes. METHODS In this randomized, double-blind, double-dummy, parallel-group trial, patients were randomized to taspoglutide 10 mg(More)
  • 1